Ask AI
ProCE Banner Activity

An Interactive Treatment Decision Support Tool for Extensive-Stage SCLC

Clinical Thought
Read this expert commentary for an overview of our new treatment decision support tool for extensive-stage small-cell lung cancer, which provides treatment recommendations from 5 lung cancer experts for your patients with newly diagnosed and relapsed/refractory disease.

Released: May 26, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Anne Chiang, MD, PhD, FASCO

Associate Professor of Medicine
Division of Thoracic Medical Oncology
Yale University School of Medicine
Associate Yale Cancer Center Director, Clinical Initiatives
New Haven, Connecticut

Anne Chiang, MD, PhD, has disclosed that she has received consulting fees from AstraZeneca, Genentech/Roche, and Jazz Pharmaceuticals and funds for research support from Amgen, AstraZeneca, Bristol-Myers Squibb, and Stemcentrx.